4 years ago

Baseimmune Raises £685K for AI-Powered Variant-Proof Vaccines

  • Baseimmune, a UK biotech startup developing variant-proof vaccines using AI, has secured £685K in seed funding

  • The round was led by Creator Fund, with participation from Mike Watson, ex-president of Moderna's infectious disease spin-out, Vaccitech, Oxford University, Maki VC, and Rockmount Seed Investments

  • Baseimmune's technology focuses on creating 'future-proof' antigens that protect against future variants of infections and circulating strains

  • The company is developing vaccines for various diseases, including COVID-19 and Malaria, in collaboration with leading academic institutions like Imperial College London and Oxford University.

      • ProblemTechnology

      "Current vaccines are not effective against new variants of viruses, requiring constant updates and new vaccines. This is a major problem for diseases like influenza, where new strains emerge every year, and for emerging diseases like COVID-19, where new variants can quickly become dominant."

      Solution

      "Baseimmune uses AI to design vaccines that are effective against both current and future variants of viruses. Their technology identifies 'future-proof' antigens that are less likely to mutate, ensuring that the vaccine remains effective even as the virus evolves. This approach could lead to vaccines that provide long-lasting protection against a wider range of viral strains, reducing the need for frequent booster shots."

      Covered on